- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Medicamen Biotech Limited — Important, 03-09-2026: Updates
03-09-2026 | 05:34 pm
03-09-2026 | 05:34 pm
Medicamen Biotech's FY26 saw consolidated revenue grow 21.66% to ₹197.77 Cr, with PAT jumping 49.43% to ₹9.80 Cr. Domestic sales surged 71% via Medicamen Life Sciences. Key developments include international expansion, CDMO wins, and oncology division growth. The company incurred ₹1.18 Lakh in fines for compliance issues.
No comments yet. Be the first to comment!